Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day

被引：18
作者：
Boulin, M. [1 ]
Delhom, E. [2 ,3 ]
Pierredon-Foulongne, M. -A. [2 ,3 ]
Cercueil, J. -P. [4 ]
Guiu, B. [2 ,3 ]
机构：
[1] Dijon Univ Hosp, Dept Pharm, F-21000 Dijon, France
[2] St Eloi Univ Hosp, Dept Radiol, F-34295 Montpellier, France
[3] Fac Med, F-34295 Montpellier, France
[4] Dijon Univ Hosp, Dept Radiol, F-21000 Dijon, France
来源：
DIAGNOSTIC AND INTERVENTIONAL IMAGING | 2015年 / 96卷 / 06期
关键词：
Liver; Carcinoma; Transarterial chemoembolization; Therapeutic; ARTERIAL CHEMOEMBOLIZATION; LIPIODOL; SAFETY; EFFICACY; BEADS; EMBOLIZATION; DIAGNOSIS; TUMORS;
D O I：
10.1016/j.diii.2015.04.005
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Transarterial chemoembolization (TACE) is the recommended treatment for patients suffering from intermediate, B stage, hepatocellular carcinoma. Despite an undisputed pharmacokinetic advantage, TACE with microspheres has not been shown to be superior in terms of survival compared to conventional TACE using Lipiodol(R). The best guarantee to reduce toxicity and maximize the efficacy of TACE is to strictly observe the contraindications for the procedure (Child-Pugh > B8, reduced portal flow, very large tumor, any technical contraindication and renal impairment), and rigorous application of the administration requirements for the Lipiodol(R) emulsion or loaded microspheres (assessment of hepatic vascularization investigating for accessory vascularization, injection methods). Tumor response should be assessed after four weeks by CT or MRI using the modified RECIST criteria. (C) 2015 Published by Elsevier Masson SAS on behalf of the Editions francaises de radiologie.
引用
收藏
页码：607 / 615
页数：9
相关论文
共 45 条
[1]   Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology [J].
Bargellini, Irene ;
Florio, Francesco ;
Golfieri, Rita ;
Grosso, Maurizio ;
Lauretti, Dario Luca ;
Cioni, Roberto .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2014, 37 (02) :438-444
[2]   Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions [J].
Bolondi, Luigi ;
Burroughs, Andrew ;
Dufour, Jean-Francois ;
Galle, Peter R. ;
Mazzaferro, Vincenzo ;
Piscaglia, Fabio ;
Raoul, Jean Luc ;
Sangro, Bruno .
SEMINARS IN LIVER DISEASE, 2012, 32 (04) :348-359
[3]   Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial [J].
Boulin, M. ;
Hillon, P. ;
Cercueil, J. P. ;
Bonnetain, F. ;
Dabakuyo, S. ;
Minello, A. ;
Jouve, J. L. ;
Lepage, C. ;
Bardou, M. ;
Wendremaire, M. ;
Guerard, P. ;
Denys, A. ;
Grandvuillemin, A. ;
Chauffert, B. ;
Bedenne, L. ;
Guiu, B. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (11) :1301-1313
[4]  
Boulin M, 2015, EUR RADIOL IN PRESS
[5]   Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma [J].
Boulin, Mathieu ;
Guiu, Severine ;
Chauffert, Bruno ;
Aho, Serge ;
Cercueil, Jean-Pierre ;
Ghiringhelli, Francois ;
Krause, Denis ;
Fagnoni, Philippe ;
Hillon, Patrick ;
Bedenne, Laurent ;
Guiu, Boris .
ANTI-CANCER DRUGS, 2011, 22 (08) :741-748
[6]  
BREEDIS C, 1954, AM J PATHOL, V30, P969
[7]   Hepatocellular carcinoma: clinical frontiers and perspectives [J].
Bruix, Jordi ;
Gores, Gregory J. ;
Mazzaferro, Vincenzo .
GUT, 2014, 63 (05) :844-855
[8]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[9]   Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[10]   Diagnosis of hepatocellular carcinoma [J].
Cartier, V. ;
Aube, C. .
DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2014, 95 (7-8) :709-719
12345